{
    "organizations": [],
    "uuid": "eba2a8622d958f5ff986ea99f579bac69956055f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-johnson-johnson-says-zytiga-approv/brief-johnson-johnson-says-zytiga-approved-for-treatment-of-prostate-cancer-idUSFWN1PY127",
    "ord_in_thread": 0,
    "title": "BRIEF-Johnson & Johnson says ZYTIGA Approved For Treatment Of Prostate Cancer",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 8 (Reuters) - Johnson & Johnson:\n* ZYTIGAÂ® (ABIRATERONE ACETATE) PLUS PREDNISONE APPROVED FOR TREATMENT OF EARLIER FORM OF METASTATIC PROSTATE CANCER\n* JANSSEN - PHASE 3 LATITUDE CLINICAL TRIAL DATA DEMONSTRATED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS IN PATIENTS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-08T21:29:00.000+02:00",
    "crawled": "2018-02-09T16:29:28.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "johnson",
        "johnson",
        "abiraterone",
        "acetate",
        "plus",
        "prednisone",
        "approved",
        "treatment",
        "earlier",
        "form",
        "metastatic",
        "prostate",
        "cancer",
        "janssen",
        "phase",
        "latitude",
        "clinical",
        "trial",
        "data",
        "demonstrated",
        "statistically",
        "significant",
        "clinically",
        "meaningful",
        "improvement",
        "patient",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}